Tyrosine Kinase/Adaptors
Tyrosine kinase and adaptor inhibitors are compounds that target tyrosine kinases and their associated adaptor proteins, which play pivotal roles in cell signaling, growth, and differentiation. These inhibitors are essential tools in cancer research, as many tyrosine kinases are involved in the signaling pathways that drive tumor growth and metastasis. By inhibiting tyrosine kinases, these compounds can block critical signaling cascades, offering potential therapeutic strategies for various cancers and other diseases involving abnormal cell signaling. At CymitQuimica, we provide a comprehensive range of high-quality tyrosine kinase and adaptor inhibitors to support your research in oncology, molecular biology, and targeted therapy development.
Subcategories of "Tyrosine Kinase/Adaptors"
- ALK(112 products)
- CSF-1R(42 products)
- EGFR(572 products)
- Ephrin Receptor(23 products)
- FLT(92 products)
- Fibroblast Growth Factor Receptor (FGFR)(169 products)
- HER(5 products)
- Hck(3 products)
- IGF-1R(88 products)
- PDGFR(126 products)
- PYK2(7 products)
- Src(79 products)
- TAM Receptor(32 products)
- Tie-2(20 products)
- Trk receptor(59 products)
- Tyrosine Kinases(26 products)
- VEGFR(268 products)
- c-Fms(108 products)
- c-Kit(101 products)
- c-Met/HGFR(128 products)
- c-RET(51 products)
Show 13 more subcategories
Found 1370 products of "Tyrosine Kinase/Adaptors"
Sort by
Purity (%)
0
100
|
0
|
50
|
90
|
95
|
100
PD-089828
CAS:<p>PD 089828 inhibits FGFR1, PDGFRβ, EGFR (IC50s: 0.15-5.47 μM), and c-Src (IC50: 0.18 μM).</p>Formula:C18H18Cl2N6OPurity:97.39%Color and Shape:SolidMolecular weight:405.28BPR1J-097
CAS:<p>BPR1J-097) is a novel FLT-3 inhibitor(IC50: 11±7 nM) with promising in vivo anti-tumor activities. It also inhibits FLT-3 D835Y (IC50: 3 nM).</p>Formula:C27H28N6O3SPurity:99.3%Color and Shape:SolidMolecular weight:516.61Nazartinib
CAS:<p>Nazartinib (EGF816) (EGF816, NVS-816) is a covalent, irreversible, mutant-selective EGFR inhibitor that has nanomolar inhibitory potency against activating mt (</p>Formula:C26H31ClN6O2Purity:98.63% - ≥95%Color and Shape:Solid PowderMolecular weight:495.02UNC2025
CAS:<p>UNC2025 (mrx-6313)(IC50 of 0.74 nM and 0.8 nM) is a potent and orally bioavailable dual MER/FLT3 inhibitor.</p>Formula:C28H40N6OPurity:99.53% - 99.74%Color and Shape:SolidMolecular weight:476.66NT157
CAS:<p>NT157, a small tyrphostin, inhibits IRS, IGF-1R, and STAT3 in TME, reducing cancer cell survival.</p>Formula:C16H14BrNO5SPurity:99.64%Color and Shape:SolidMolecular weight:412.26ENMD-2076
CAS:<p>ENMD-2076, a multi-targeted kinase inhibitor, has specific activity against Aurora A, Flt3, KDR/VEGFR2, Flt4/VEGFR3, FGFR1, FGFR2, Src, PDGFRα.</p>Formula:C21H25N7Purity:97.63% - ≥95%Color and Shape:SolidMolecular weight:375.47Motesanib
CAS:<p>Motesanib (AMG 706) orally blocks VEGFR, PDGFR, Kit, Ret; curbing angiogenesis and cancer cell growth.</p>Formula:C22H23N5OPurity:98% - 99.09%Color and Shape:SolidMolecular weight:373.45hVEGF-IN-1
CAS:<p>hVEGF-IN-1 inhibits human VEGF-A translation and has antitumor activity.</p>Formula:C34H43N7O2Purity:99.76% - >99.99%Color and Shape:SolidMolecular weight:581.75KHS101 hydrochloride
CAS:<p>KHS101 is a TACC3 inhibitor and can selectively induce a neuronal differentiation phenotype.</p>Formula:C18H22ClN5SPurity:99.6%Color and Shape:SolidMolecular weight:375.92S49076
CAS:<p>S49076 is a novel, potent inhibitor of MET, AXL/MER, and FGFR1/2/3, blocking cellular phosphorylation of MET, AXL, and FGFRs.</p>Formula:C22H22N4O4SPurity:95.35% - 97.4%Color and Shape:SolidMolecular weight:438.5PD153035
CAS:<p>PD153035 (NSC-669364) hydrochloride is an effective and selective inhibitor of EGFR (Ki/IC50: 5.2/29 pM, in cell-free assays); little inhibitory against FGFR,</p>Formula:C16H14BrN3O2Purity:98.47% - 99.29%Color and Shape:SolidMolecular weight:360.21SU4312
CAS:<p>SU-4312 (DMBI) inhibits VEGFR & PDGFR (IC50: 0.8, 19.4 μM) and shields neurons from MPP(+)-induced damage by blocking nNOS.</p>Formula:C17H16N2OPurity:>99.99%Color and Shape:SolidMolecular weight:264.32Tuxobertinib
CAS:<p>Tuxobertinib (BDTX-189) is a potent and selective inhibitor of allosteric EGFR and HER2 oncogenic mutations. BDTX-189 exhibits anticancer activity.</p>Formula:C29H29ClN6O4Purity:99.22%Color and Shape:SolidMolecular weight:561.03Sitravatinib
CAS:<p>Sitravatinib (MGCD516) (MGCD516) is an inhibitor targeting multiple RTKs involved in driving sarcoma cell growth, including c-Met, c-Kit, PDGFRα/β, PDGFR, and</p>Formula:C33H29F2N5O4SPurity:98.9% - 99.85%Color and Shape:SolidMolecular weight:629.68ODM-203
CAS:<p>ODM-203, a Selective Inhibitor of FGFR and VEGFR, Shows Strong Antitumor Activity, and Induces Antitumor Immunity</p>Formula:C26H21F2N5O2SPurity:99.85%Color and Shape:SolidMolecular weight:505.54Afatinib
CAS:<p>Afatinib (BIBW 2992) is an irreversible and orally EGFR family inhibitor that inhibits EGFR and HER2. Afatinib has antitumor activity. Cost effective and quality assured.</p>Formula:C24H25ClFN5O3Purity:98.56% - 99.9%Color and Shape:Off-White SolidMolecular weight:485.94PRT-060318
CAS:<p>PRT-060318 (P142-76) is a novel selective inhibitor of the Syk tyrosine kinase, as an approach to HIT treatment.</p>Formula:C18H24N6OPurity:99.98%Color and Shape:SolidMolecular weight:340.42DDR1-IN-2
CAS:<p>DDR1-IN-2 (DDR1 inhibitor 7rh) (DDR1 inhibitor 7rh) is a potent, selective, ATP-competitive Discoidin domain receptor 1 (DDR1) inhibitor (IC50: 6.8 nM in cell-</p>Formula:C30H29F3N6OPurity:97.51%Color and Shape:SolidMolecular weight:546.59LDN-192960
CAS:<p>LDN-192960 is a potent inhibitor of Haspin and DYRK2 (IC50s: 10 nM and 48 nM).</p>Formula:C18H20N2O2SPurity:98.01% - 99.51%Color and Shape:SolidMolecular weight:328.43SU14813
CAS:<p>SU14813: inhibits multiple kinases (VEGFR2, VEGFR1, PDGFRβ, KIT) with IC50s of 50, 2, 4, 15 nM; antiangiogenic and antitumor.</p>Formula:C23H27FN4O4Purity:98.13%Color and Shape:SolidMolecular weight:442.48Gandotinib
CAS:<p>LY2784544(Gandotinib (LY2784544)) is a potent JAK2 inhibitor (IC50: 3 nM), effective in JAK2V617F(Ki: 0.245 nM).</p>Formula:C23H25ClFN7OPurity:99.33% - 99.86%Color and Shape:SolidMolecular weight:469.94zanubrutinib
CAS:<p>Zanubrutinib (BGB-3111) is an inhibitor of Bruton tyrosine kinase (BTK).</p>Formula:C27H29N5O3Purity:98.42% - 99.76%Color and Shape:SolidMolecular weight:471.55Belizatinib
CAS:<p>Belizatinib (TSR-011) is an effective, oral and dual inhibitor of ALK (IC50: 0.7 nM, wild-type recombinant ALK) and TRKA, TRKB, and TRKC.</p>Formula:C33H44FN5O3Purity:99.33% - 99.44%Color and Shape:SolidMolecular weight:577.73Ningetinib Tosylate
CAS:<p>Ningetinib Tosylate is an orally bioavailable tyrosine kinase inhibitor with IC50s of <1.0, 1.9 and 6.7 nM for Axl, VEGFR2, and c-Met, respectively.</p>Formula:C38H37FN4O8SPurity:99.93%Color and Shape:SolidMolecular weight:728.79AIM-100
CAS:<p>AIM-100 is a Ack1 inhibitor (IC50: 24 nM).</p>Formula:C23H21N3O2Purity:98.91%Color and Shape:SolidMolecular weight:371.43BBT594
CAS:<p>BBT594 (NVP-BBT594)(NVP-BBT594) is a potent inhibitor of receptor tyrosine kinase RET,Treatment of cancer.</p>Formula:C28H30F3N7O3Purity:99.57%Color and Shape:SolidMolecular weight:569.58Epidermal Growth Factor
CAS:<p>EGF binds EGFR, promotes cell growth & heals diabetic foot ulcers.</p>Formula:C270H401N73O83S7Purity:97.17%Color and Shape:SolidMolecular weight:6222NVP-BVU972
CAS:<p>NVP-BVU972 is a selective and potent Met inhibitor with IC50 of 14 nM.</p>Formula:C20H16N6Purity:97.24% - >99.99%Color and Shape:SolidMolecular weight:340.38EAI045
CAS:<p>EAI045, an allosteric inhibitor, targets towards drug-resistant EGFR mutants but avoids the wild-type receptor.</p>Formula:C19H14FN3O3SPurity:98.00% - 99.12%Color and Shape:SolidMolecular weight:383.4Ibrutinib deacryloylpiperidine
CAS:<p>Ibrutinib deacryloylpiperidine (IBT4A) is a highly selective Bruton’s tyrosine kinase (BTK) irreversible inhibitor with an IC50 of 0.5 nM.</p>Formula:C17H13N5OPurity:99.47%Color and Shape:SolidMolecular weight:303.32NRC-2694 hydrochloride
CAS:<p>NRC-2694 hydrochloride is an epidermal growth factor receptor (EGFR) antagonist potentially for the treatment of solid tumors.</p>Formula:C24H27ClN4O3Color and Shape:SolidMolecular weight:454.95CUDC-101
CAS:<p>CUDC-101 is a potent inhibitor of HDAC, EGFR and HER2 with IC50s of 4.4, 2.4 and 15.7 nM, respectively.</p>Formula:C24H26N4O4Purity:95.76% - 99.17%Color and Shape:SolidMolecular weight:434.49Oclacitinib maleate
CAS:<p>Oclacitinib maleate is a selective JAK inhibitor (IC50: 10-99 nM; JAK1 cytokines: 36-249 nM), with no effect on 38 non-JAK kinases.</p>Formula:C15H23N5O2S·C4H4O4Purity:99.17%Color and Shape:SolidMolecular weight:453.51CP-380736
CAS:<p>CP-380736 (PF-00520893) inhibits EGFR, a kinase key in cancer-signaling pathways like MAPK, JNK, and Akt.</p>Formula:C14H18N2O5Purity:99.68%Color and Shape:White To Off-White SolidMolecular weight:294.3Mobocertinib
CAS:<p>Mobocertinib (tak788) is a potent inhibitor of epidermal growth factor receptor (EGFR) and an antineoplastic agent</p>Formula:C32H39N7O4Purity:99.47% - 99.97%Color and Shape:SolidMolecular weight:585.7Gefitinib-based PROTAC 3
CAS:<p>Gefitinib-PROTAC 3 degrades EGFR in cancer cells; DC50s: 11.7 nM (HCC827) and 22.3 nM (H3255).</p>Formula:C47H57ClFN7O8SPurity:97.29% - 98.25%Color and Shape:SolidMolecular weight:934.51(Rac)-IBT6A
CAS:<p>(Rac)-IBT6A is a racemate of IBT6A. IBT6A is an impurity of Ibrutinib and can be used in the synthesis of IBT6A Ibrutinib dimer and IBT6A adduct.</p>Formula:C22H22N6OPurity:99.24%Color and Shape:SolidMolecular weight:386.45WHI-P258
CAS:<p>WHI-P258, a weak JAK3 inhibitor, is used as a negative control in drug development.</p>Formula:C16H15N3O2Purity:99.66% - 99.92%Color and Shape:SolidMolecular weight:281.31Repotrectinib
CAS:<p>Repotrectinib (TPX-0005) is a potent ALK/ROS1/TRK inhibitor, with IC50 of 1.01/5.3/1.08/1.26 nM for WT ALK, SRC, ALK L1196M and ALK G1202R, respectively.</p>Formula:C18H18FN5O2Purity:99.92% - >99.99%Color and Shape:SolidMolecular weight:355.37squarunkinA
CAS:<p>squarunkinA is a novel modulator of the UNC119-Cargo Interaction, potently and selectively inhibiting the binding of a myristoylated peptide representing the N-</p>Formula:C25H32F3N5O4Purity:99.29%Color and Shape:SolidMolecular weight:523.55Malantide acetate(86555-35-3 free base)
<p>Malantide acetate is a dodecapeptide phosphorylated by cyclic AMP-dependent protein kinase (PKA), and increases PKA activity.Malantide is a synthetic peptide</p>Formula:C74H128N22O23Purity:>99.99%Color and Shape:SolidMolecular weight:1693.97R-268712
CAS:<p>R-268712 is a potent ALK5 inhibitor with a 2.5 nM IC50, also targeting TGF-β type I receptor orally.</p>Formula:C20H18FN5OPurity:99.61%Color and Shape:SolidMolecular weight:363.39MSDC 0160
CAS:<p>MSDC 0160 (CAY10415) is a prototype mTOT-modulating insulin sensitizer being used in trials studying the treatment of Type 2 Diabetes and Alzheimer's Disease.</p>Formula:C19H18N2O4SPurity:98.11% - 99.53%Color and Shape:SolidMolecular weight:370.42UNC2541
CAS:<p>UNC2541 is a potent and Mer tyrosine kinase (MerTK)-specific inhibitor.</p>Formula:C24H34FN7O2Purity:98.33%Color and Shape:SolidMolecular weight:471.57Derazantinib dihydrochloride
CAS:<p>Derazantinib, a multi-kinase inhibitor targeting FGFR, benefits FGFR2-positive iCCA; its dihydrochloride form is a salt variant.</p>Formula:C29H31Cl2FN4OColor and Shape:SolidMolecular weight:541.49Almonertinib
CAS:<p>Almonertinib (HS-10296) is an inhibitor of EGFR activation mutation and tolerant mutation of EGFR T790M, which has only limited activity against wild-type EGFR.</p>Formula:C30H35N7O2Purity:99.99%Color and Shape:SolidMolecular weight:525.64PKI 14-22 amide, myristoylated Acetate
<p>PKI 14-22 amide, myristoylated Acetate inhibit cAMP-dependent protein kinase (PKA) and blocks hyperalgesia produced by spinal administration of 8-bromo-cAMP. </p>Formula:C55H104N20O14Purity:96.34%Color and Shape:SolidMolecular weight:1269.54SU5205
CAS:<p>SU5205 is a VEGFR2 inhibitor.</p>Formula:C15H10FNOPurity:99.62% - 99.67%Color and Shape:SolidMolecular weight:239.24WZ8040
CAS:<p>WZ8040 is a novel mutant-selective irreversible EGFRT790M inhibitor, does not inhibit ERBB2 phosphorylation (T798I).</p>Formula:C24H25ClN6OSPurity:97.42% - 99.785%Color and Shape:SolidMolecular weight:481.01Merestinib
CAS:<p>Merestinib (LY2801653) is an orally available, small molecule inhibitor of the proto-oncogene c-Met (Ki: 2 nM) with potential antineoplastic activity.</p>Formula:C30H22F2N6O3Purity:95% - 99.71%Color and Shape:SolidMolecular weight:552.53
